Hyperglycemic Emergencies: Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State

---

ONLINE

Wednesday, May 15, 2024, 12:00 AM - Friday, May 14, 2027, 11:59 PM


AMA PRA Category 1 Credits™ (0.75 hours), AAPA Category 1 CME (0.75 hours), ANCC - Nursing Contact Hour(s) (0.75 hours), Non-Physician Attendance (0.75 hours)

Adequate glycemic control in patients with or without diabetes is an essential aspect of overall of cancer care. Hyperglycemia during hospitalization is associated with increased risk of complications and extended hospital stay. This module is designed to introduce basal-bolus insulin therapy as the standard of treatment for inpatient hyperglycemia. The module focuses on the foundational concepts of basal-bolus insulin therapy which include: components of BBI, advantages of BBI over sliding scale insulin (SSI), and collaborative care strategies in the care of patients with hyperglycemia in the inpatient settings. This enduring material designed for the interprofessional healthcare team to be able to identify patients with Diabetic Ketoacidosis (DKA), and Hyperosmolar Hyperglycemic State (HHS) and summarize collaborative care strategies.

1. Identify the risk factors and precipitating factors of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS).
2. Summarize DKA/HHS collaborative care strategies.
3. Identify the early signs symptoms that suggest DKA/HHS.

Participants may access and complete the course in the online Education Center (Taleo Learn). There is no registration fee for this educational activity.


RELEASE DATE: May 15, 2024
EXPIRATION DATE: May 14, 2027
Estimated time to complete:  45 minutes

Content:
Please click on the Education Center link to be re-directed to the Education Center and prompted to login. 
Once logged in, type in 'Hyperglycemic Emergencies' in the search bar to locate the activity. 

Education Center

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this enduring material will award 0.75 Nursing Contact Hour(s).

The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until May 14, 2027. PAs should only claim credit commensurate with the extent of their participation.

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.